Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) and Rockwell Medical (NASDAQ:RMTI – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, earnings, risk and institutional ownership.
Insider and Institutional Ownership
21.7% of Capricor Therapeutics shares are owned by institutional investors. Comparatively, 23.3% of Rockwell Medical shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Comparatively, 3.6% of Rockwell Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Capricor Therapeutics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500. Comparatively, Rockwell Medical has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Capricor Therapeutics | 1 | 0 | 7 | 1 | 2.89 |
| Rockwell Medical | 1 | 0 | 2 | 1 | 2.75 |
Capricor Therapeutics presently has a consensus target price of $22.25, suggesting a potential upside of 197.46%. Rockwell Medical has a consensus target price of $4.00, suggesting a potential upside of 230.58%. Given Rockwell Medical’s higher probable upside, analysts plainly believe Rockwell Medical is more favorable than Capricor Therapeutics.
Profitability
This table compares Capricor Therapeutics and Rockwell Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Capricor Therapeutics | N/A | -62.71% | -50.82% |
| Rockwell Medical | -2.38% | -6.79% | -3.77% |
Valuation and Earnings
This table compares Capricor Therapeutics and Rockwell Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Capricor Therapeutics | $22.27 million | 15.36 | -$40.47 million | ($1.64) | -4.56 |
| Rockwell Medical | $101.49 million | 0.41 | -$480,000.00 | ($0.06) | -20.17 |
Rockwell Medical has higher revenue and earnings than Capricor Therapeutics. Rockwell Medical is trading at a lower price-to-earnings ratio than Capricor Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Rockwell Medical beats Capricor Therapeutics on 8 of the 14 factors compared between the two stocks.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
